Romiplostim as a Therapeutic Intervention for Tacrolimus-induced Immune Thrombocytopenia in a Pediatric Cardiac Transplant Patient
| Autor: | L. Vandy Black, Robert P Seifert, Trisha Larkin, Daniel R Gipson |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Agonist Pediatrics medicine.medical_specialty medicine.drug_class Recombinant Fusion Proteins chemical and pharmacologic phenomena Receptors Fc Tacrolimus immune system diseases hemic and lymphatic diseases Intervention (counseling) medicine Humans Child Thrombopoietin receptor Purpura Thrombocytopenic Idiopathic Romiplostim business.industry Hematology Immune thrombocytopenia Discontinuation Transplantation surgical procedures operative Thrombopoietin Oncology Pediatrics Perinatology and Child Health Heart Transplantation business Immunosuppressive Agents medicine.drug |
| Zdroj: | Journal of Pediatric Hematology/Oncology. 43:e777-e779 |
| ISSN: | 1077-4114 |
| DOI: | 10.1097/mph.0000000000001994 |
| Popis: | Tacrolimus-induced immune thrombocytopenia (ITP) is a rare entity that can occur years after initiation of tacrolimus therapy following solid organ transplantation, and platelet recovery can be substantially delayed following discontinuation of tacrolimus. Romiplostim, a thrombopoietin receptor agonist approved by the FDA in 2018 for the treatment of chronic ITP in children, may be a useful therapy to hasten platelet recovery in the acute ITP setting in place of immunomodulating agents. We present a case of tacrolimus-induced ITP successfully treated with romiplostim in a child following cardiac transplantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|